418 related articles for article (PubMed ID: 28283896)
1. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
Syed YY
Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
[TBL] [Abstract][Full Text] [Related]
2. Fluocinolone acetonide for the treatment of diabetic macular edema.
Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P
Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565
[TBL] [Abstract][Full Text] [Related]
3. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
Sanford M
Drugs; 2013 Feb; 73(2):187-93. PubMed ID: 23335133
[TBL] [Abstract][Full Text] [Related]
4. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Soubrane G; Behar-Cohen F
J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
[TBL] [Abstract][Full Text] [Related]
5. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
6. Intravitreal steroids for macular edema in diabetes.
Rittiphairoj T; Mir TA; Li T; Virgili G
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
[TBL] [Abstract][Full Text] [Related]
7. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study.
Cutino A; Green K; Kendall R; Moore PT; Zachary C
Am J Manag Care; 2015 Jan; 21(4 Suppl):S63-72. PubMed ID: 25734663
[TBL] [Abstract][Full Text] [Related]
9. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.
Holden SE; Currie CJ; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149
[TBL] [Abstract][Full Text] [Related]
11. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
Currie CJ; Holden SE; Berni E; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
[TBL] [Abstract][Full Text] [Related]
13. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.
Alfaqawi F; Lip PL; Elsherbiny S; Chavan R; Mitra A; Mushtaq B
Eye (Lond); 2017 Apr; 31(4):650-656. PubMed ID: 28106887
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.
Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J;
Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
[TBL] [Abstract][Full Text] [Related]
16. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
Panos GD; Arruti N; Patra S
Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704
[TBL] [Abstract][Full Text] [Related]
17. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
[TBL] [Abstract][Full Text] [Related]
18. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
[TBL] [Abstract][Full Text] [Related]
19. A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND).
Figueira J; Henriques J; Amaro M; Rosas V; Alves D; Cunha-Vaz J
Ophthalmic Res; 2017; 57(3):166-172. PubMed ID: 28178701
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
